trial

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

NCTId NCT07565428
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 380 (estimated)
Sponsored by Minerva Neurosciences
Primary completion 2027-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
380 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-04-23
Primary completion
2027-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
RoluperidoneRisperidoneAripiprazoleOlanzapine

Sponsors

Minerva NeurosciencesLead Sponsor

Sites

5 total
Culver City, United StatesTampa, United StatesGaithersburg, United StatesMarlton, United StatesRichardson, United States

Linked catalysts

1
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Neg — primary completion2027-12

Facts & assertions

4 sourced
Enrollment
380
Phase
PHASE3
Primary Completion Date
2027-12
Status
RECRUITING
relationships
The graph out of here
drug
Roluperidone
drug
Risperidone
drug
Aripiprazole
drug
Olanzapine
drug
lead_sponsor
Minerva Neurosciences
company
indication
Negative Symptoms of Schizophrenia
indication